Мобильная версия

Доступно журналов:

3 288

Доступно статей:

3 891 637

 

Скрыть метаданые

Автор Jacobs, LD
Автор Cookfair, DL
Автор Rudick, RA
Автор Herndon, RM
Автор Richert, JR
Автор Salazar, AM
Автор Fischer, JS
Автор Goodkin, DE
Автор Granger, CV
Автор Simon, JH
Автор (deceased), LJ, Emrich
Автор Bartoszak, DM
Автор Bourdette, DN
Автор Braiman, J
Автор Brownscheidle, CM
Автор Coats, ME
Автор Cohan, SL
Автор Dougherty, DS
Автор Kinkel, RP
Автор Mass, MK
Автор III, FE, Munschauer
Автор Priore, RL
Автор Pullicino, PM
Автор Scherokman, BJ
Автор Weinstock-Guttman, B
Автор Whitham, RH
Дата выпуска 1995
dc.description The design and conduct of a randomized, double-blinded, placebo-controlled, multicenter, phase III study of recombinant interferon beta-1a (IFN-β-1a) as treatment for exacerbating-remitting MS are described, as are baseline characteristics of the study population. The purpose of the study was to determine if 6.0 × 10<sup>6</sup> IU (30 μg) of IFN-β-1a, administered by weekly intramuscular (i.m.) injections, was effective in delaying the onset of sustained disability. The primary outcome measure was time to onset of treatment failure, defined as a worsening on the Kurtzke Expanded Disability Status Scale (EDSS) of greater than or equal to 1.0 point compared with baseline, persisting for at least 6 months. An intent-to-treat design was used. The primary outcome measure was analyzed using the Mantel-Cox log-rank statistic and Kaplan-Meier survival curves. Secondary outcomes included quantitative measures of upper and lower extremity function, neuropsychological test performance, functional and quality of life assessments and several measures derived from annual brain MRI studies. Entry criteria included prestudy exacerbation rates of at least 0.67 per year and EDSS scores of 1.0–3.5. A total of 301 MS patients were randomly assigned to receive weekly i.m. injections of IFN-β-1a or placebo. The average age of the study population at entry was 37 years; 92% were Caucasian and 73% were women. The mean prestudy disease duration was 6.5 years, mean prestudy exacerbation rate was 1.2 per year and the mean EDSS score was 2.3. The randomization yielded well-balanced treatment arms. Various aspects of the study are discussed, including: (1) the decision to focus study design on sustained disability; (2) the rationale for the treatment regimen; (3) measures taken to assure the reliability of the primary outcome measure; and (4) a description of the secondary outcome measures.
Издатель SAGE Publications
Тема interferon
Тема disability
Название A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients
Тип Journal Article
DOI 10.1177/135245859500100210
Electronic ISSN 1477-0970
Print ISSN 1352-4585
Журнал Multiple Sclerosis
Том 1
Первая страница 118
Последняя страница 135
Аффилиация Jacobs, LD, Multiple Sclerosis Research Center, Millard Fillmore Health System, Buffalo, 14209, USA
Аффилиация Cookfair, DL, MSCRG Data Management and Statistical Center, Department of Neurology, The Buffalo General Hospital, Buffalo, NY, 14203, USA
Аффилиация Rudick, RA, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA
Аффилиация Herndon, RM, Department of Neurology, Good Samaritan Hospital and Medical Center, Portland, OR, 97210, USA
Аффилиация Richert, JR, Department of Neurology, Georgetown University Medical Center, Washington, DC, 20007, USA
Аффилиация Salazar, AM, Department of Neurology, Walter Reed Army Medical Center, Washington, DC, 20307, USA
Аффилиация Fischer, JS, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA
Аффилиация Goodkin, DE, UCSF/Mount Zion Multiple Sclerosis Center, San Francisco, CA, 94115, USA
Аффилиация Granger, CV, Department of Rehabilitation Medicine, State University of New York at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, NY, 14215, USA
Аффилиация Simon, JH, Department of Radiology-MRI, University of Colorado Health Sciences Center, Denver, CO, 80262, USA
Аффилиация (deceased), LJ, Emrich, Department of Biomathematics, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA
Аффилиация Bartoszak, DM, Department of Neurology, Walter Reed Army Medical Center, Washington, DC, 20307, USA
Аффилиация Bourdette, DN, Department of Neurology, Oregon Health Sciences University, Portland, OR, 97201, USA
Аффилиация Braiman, J, Department of Neurology, Walter Reed Army Medical Center, Washington, DC, 20307, USA
Аффилиация Brownscheidle, CM, Department of Neurology, The Buffalo General Hospital, Buffalo, NY, 14203, USA
Аффилиация Coats, ME, Department of Neurology, Walter Reed Army Medical Center, Washington, DC, 20307, USA
Аффилиация Cohan, SL, Department of Neurology, Georgetown University Medical Center, Washington, DC, 20007, USA
Аффилиация Dougherty, DS, Department of Neurology, Walter Reed Army Medical Center, Washington, DC, 20307, USA
Аффилиация Kinkel, RP, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA
Аффилиация Mass, MK, Department of Neurology, Good Samaritan Hospital and Medical Center, Portland, OR, 97210, USA
Аффилиация III, FE, Munschauer, Department of Neurology, The Buffalo General Hospital, Buffalo, NY, 14203, USA
Аффилиация Priore, RL, MSCRG Data Management and Statistical Center, Department of Neurology, The Buffalo General Hospital, Buffalo, NY, 14203, USA
Аффилиация Pullicino, PM, Department of Neurology, The Buffalo General Hospital, Buffalo, NY, 14203, USA
Аффилиация Scherokman, BJ, Department of Neurology, Kaiser Permanente Medical Center, Springfield, VA, 22150, USA
Аффилиация Weinstock-Guttman, B, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA
Аффилиация Whitham, RH, Department of Neurology, Oregon Health Sciences University, Portland, OR, 97201, USA
Выпуск 2

Скрыть метаданые